enow.com Web Search

Search results

1. Results from the WOW.Com Content Network

2. Merck-AstraZeneca breast cancer drug reduces risk of ... - AOL

   www.aol.com/finance/merck-astrazeneca-breast...

   About 5% to 10% of female breast cancer patients have a BRCA mutation, according to the American Cancer Society. When breast cancer is diagnosed early, the five-year relative survival rate is over ...

3. FDA Approves AstraZeneca's Datroway For Pretreated Breast ...

   www.aol.com/finance/fda-approves-astrazenecas...

   On Friday, the U.S. Food and Drug Administration (FDA) approved AstraZeneca Plc’s (NASDAQ:AZN) Datroway (datopotamab deruxtecan or Dato-DXd) for adult patients with unresectable or metastatic ...

4. US FDA approves AstraZeneca's breast cancer drug ... - AOL

   www.aol.com/news/us-fda-approves-astrazenecas...

   The Truqap combination enters a competitive market of breast cancer treatments, which include AstraZeneca-Daiichi Sankyo's Enhertu and Gilead's Trodelvy. ... US FDA approves AstraZeneca's breast ...

5. Capivasertib - Wikipedia

   en.wikipedia.org/wiki/Capivasertib

   Capivasertib, sold under the brand name Truqap, is an anti-cancer medication used for the treatment of breast cancer. [4] [7] It is taken by mouth.[4]The most common adverse reactions include diarrhea, cutaneous adverse reactions, increased random glucose, decreased lymphocytes, decreased hemoglobin, increased fasting glucose, nausea, fatigue, decreased leukocytes, increased triglycerides ...

6. Fulvestrant - Wikipedia

   en.wikipedia.org/wiki/Fulvestrant

   Fulvestrant, sold under the brand name Faslodex among others, is an antiestrogenic medication used to treat hormone receptor (HR)-positive metastatic breast cancer in postmenopausal women with disease progression as well as HR-positive, HER2-negative advanced breast cancer in combination with abemaciclib or palbociclib in women with disease progression after endocrine therapy. [2]

7. Latest Trial Setback For AstraZeneca's Dato-DXd, The Drug ...

   www.aol.com/latest-trial-setback-astrazenecas...

   Monday, AstraZeneca Plc (NASDAQ:AZN) released high-level results from the TROPION-Breast01 Phase 3 trial of datopotamab deruxtecan (Dato-DXd) compared to the investigator’s choice of chemotherapy.

8. AstraZeneca's breast cancer drug combination fails in late ...

   www.aol.com/news/astrazenecas-breast-cancer-drug...

   (Reuters) - AstraZeneca said on Tuesday its breast cancer drug, Truqap, in combination with chemotherapy agent, paclitaxel, did not meet its main goals in a late-stage trial to improve overall ...

9. AstraZeneca (AZN) Breast Cancer Drug Cuts Risk of Death ... - AOL

   www.aol.com/news/astrazeneca-azn-breast-cancer...

   Data from a late-stage study shows that AstraZeneca's (AZN) Enhertu meets superior and clinically meaningful progression-free survival and overall survival in HER2-low metastatic breast cancer ...